Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat

Cellular Physiology and Biochemistry

Volumn 26, Issue 3, 2010, Pages 457-470

  Ma, Yukui ^a   Qiao, Xiaoying ^a   Falone, Anthony E ^a   Reslan, Ossama M ^a   Sheppard, Stephanie J ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Blood vessels; Cardiovascular disease; Estrogen; Sex hormones

Indexed keywords

ANTIESTROGEN; CALCIUM CHANNEL; DIARYLPROPIONITRILE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; PHENYLEPHRINE; POTASSIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; FEMALE; GENDER; MALE; MEMBRANE DEPOLARIZATION; MUSCLE FIBER CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

RATTUS;

EID: 78650008706     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320569     Document Type: Article

References (66)

1. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 1991;265:1861-1867.
2. Dubey RK, Imthurn B, Zacharia LC, Jackson EK: Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 2004;44:789-795.
3. Gerhard M, Ganz P: How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995;92:5-8.
4. Koledova V V, Khalil RA: Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Expert Rev Cardiovasc Ther 2007;5:777-789.
5. Mendelsohn ME, Karas RH: Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587.
6. Orshal JM, Khalil RA: Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 2004;286:R233-249.
7. Mendoza SG, Zerpa A, Carrasco H, Colmenares O, Rangel A, Gartside PS, Kashyap ML: Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. Artery 1983;12:1-23.
8. Bing RJ, Conforto A: Reversal of acetylcholine effect on atherosclerotic coronary arteries by estrogen: pharmacologic phenomenon of clinical importance? J Am Coll Cardiol 1992;20:458-459.
9. Wolinsky H: Effects of estrogen and progestogen treatment on the response of the aorta of male rats to hypertension. Morphological and chemical studies. Circ Res 1972;30:341-349.
10. Serock MR, Wells AK, Khalil RA: Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov 2008;3:165-186.
11. Gisclard V, Miller VM, Vanhoutte PM: Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988;244:19-22.
12. Herrington DM, Braden GA, Williams JK, Morgan TM: Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-952.
13. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol. 1999;19:1034-1040.
14. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P: Endothelium-independent relaxation of rabbit coronary artery by 17beta-oestradiol in vitro. Br J Pharmacol 1991;104:1033-1307.
15. Smiley DA, Khalil RA: Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem 2009;16:1863-1887.
16. Chambliss KL, Yuhanna IS, Mineo C, Liu P, German Z, Sherman TS, Mendelsohn ME, Anderson RG, Shaul PW: Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res 2000;87:E44-52.
17. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME: Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002;90:1087-1092.
18. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, Gustafsson JA, Mendelsohn ME: Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002;295:505-508.
19. Mendelsohn ME: Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002;90:3F-6F.
20. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, Thomas P: Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007;148:3236-3245.
21. Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH, Heigl A, Lachat M, Genoni M, Barton M: Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007;49:1358-1363.
22. Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB: The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol 2008;109:350-353.
23. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005;307:1625-1630.
24. Barber DA, Miller VM: Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am J Physiol 1997;273:H2325-2332.
25. 2+ entry mechanisms of vasoconstriction in Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 1999;34:931-936.
26. Matsumoto T, Kakami M, Kobayashi T, Kamata K: Gender differences in vascular reactivity to endothelin-1 (1-31) in mesenteric arteries from diabetic mice. Peptides 2008;29:1338-1346.
27. Miller VM, Barber DA, Fenton AM, Wang X, Sieck GC: Gender differences in response to endothelin-1 in coronary arteries: transcription, receptors and calcium regulation. Clin Exp Pharmacol Physiol 1996;23:256-259.
28. i in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol 2000;278:C834-844.
29. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, Couse JF, Curtis SW, Korach KS: Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997;99:2429-2437.
30. Tostes RC, David FL, Carvalho MH, Nigro D, Scivoletto R, Fortes ZB: Gender differences in vascular reactivity to endothelin-1 in deoxycorticosterone-salt hypertensive rats. J Cardiovasc Pharmacol 2000;36:S99-101.
31. Varbiro S, Matrai M, Szekeres M, Nadasy GL, Szaky E, Mericli M, Banhidy F, Monos E, Szekacs B: Intramural coronary artery constrictor reactivity to thromboxane is higher in male than in female rats. Gynecol Endocrinol 2006;22:44-47.
32. Geary GG, Krause DN, Duckles SP: Estrogen reduces myogenic tone through a nitric oxide-dependent mechanism in rat cerebral arteries. Am J Physiol 1998;275:H292-300.
33. Li Z, Krause DN, Doolen S, Duckles SP: Ovariectomy eliminates sex differences in rat tail artery response to adrenergic nerve stimulation. Am J Physiol 1997;272:H1819-1825.
34. Khalil RA, Morgan KG: Phenylephrine-induced translocation of protein kinase C and shortening of two types of vascular cells of the ferret. J Physiol 1992;455:585-599.
35. Nayler WG, Perry SE, Elz JS, Daly MJ: Calcium, sodium, and the calcium paradox. Circ Res 1984;55:227-237.
36. Khalil RA, van Breemen C: Sustained contraction of vascular smooth muscle: calcium influx or C-kinase activation? J Pharmacol Exp Ther 1988;244:537-542.
37. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA: Pyrazole ligands: structure-affinity/ activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 2000;43:4934-4947.
38. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS: Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 1999;140:800-804.
39. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS: Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 2003;206:13-22.
40. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000;14:1649-1660.
41. Kleuser B, Malek D, Gust R, Pertz HH, Potteck H: 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol 2008;74:1533-1543.
42. 2+ -independent isoforms of protein kinase C differentially translocate in smooth muscle. Am J Physiol 1992;263:C714-719.
43. Khalil RA, Morgan KG: Imaging of protein kinase C distribution and translocation in living vascular smooth muscle cells. Circ Res 1991;69:1626-1631.
44. Kanashiro CA, Khalil RA: Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol 2001;280:C34-45.
45. Lin AL, Shain SA: Estrogen-mediated cytoplasmic and nuclear distribution of rat cardiovascular estrogen receptors. Arteriosclerosis 1985;5:668-677.
46. Dan P, Cheung JC, Scriven DR, Moore ED: Epitope-dependent localization of estrogen receptor-alpha, but not -beta, in en face arterial endothelium. Am J Physiol Heart Circ Physiol 2003;284:H1295-1306.
47. Raffetto JD, Qiao X, Beauregard KG, Khalil RA: Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins. J Vasc Surg 2010;51:972-981.
48. Malorni W, Straface E, Matarrese P, Ascione B, Coinu R, Canu S, Galluzzo P, Marino M, Franconi F: Redox state and gender differences in vascular smooth muscle cells. FEBS Lett 2008;582:635-642.
49. Straface E, Vona R, Gambardella L, Ascione B, Marino M, Bulzomi P, Canu S, Coinu R, Rosano G, Malorni W, Franconi F: Cell sex determines anoikis resistance in vascular smooth muscle cells. FEBS Lett 2009;583:3448-3454.
50. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Tan J, Meldrum DR: Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2008;295:R1486-1493.
51. Montgomery S, Shaw L, Pantelides N, Taggart M, Austin C: Acute effects of oestrogen receptor subtype-specific agonists on vascular contractility. Br J Pharmacol 2003;139:1249-1253.
52. Bolego C, Cignarella A, Sanvito P, Pelosi V, Pellegatta F, Puglisi L, Pinna C: The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation. J Pharmacol Exp Ther 2005;313:1203-1208.
53. Cruz MN, Agewall S, Schenck-Gustafsson K, Kublickiene K: Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease. Atherosclerosis 2008;196:49-58.
54. Luksha L, Kublickiene K: The role of estrogen receptor subtypes for vascular maintenance. Gynecol Endocrinol 2009;25:82-95.
55. Luksha L, Poston L, Gustafsson JA, Hultenby K, Kublickiene K: The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J Physiol 2006;577:945-955.
56. 2+ currents in aortic smooth muscle cells. Eur J Pharmacol 1995;294:625-635.
57. 2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol. 1994;266:C975-980.
58. Landers JP, Spelsberg TC: New concepts in steroid hormone action: transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit Rev Eukaryot Gene Expr 1992;2:19-63.
59. Schnoes KK, Jaffe IZ, Iyer L, Dabreo A, Aronovitz M, Newfell B, Hansen U, Rosano G, Mendelsohn ME: Rapid recruitment of temporally distinct vascular gene sets by estrogen. Mol Endocrinol 2008;22:2544-2556.
60. Doan T, Farmer P, Cooney T, Ali MS: Selective down-regulation of angiotensin II receptor type 1A signaling by protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells. Cell Signal 2004;16:301-311.
61. Ishihata A, Tasaki K, Katano Y: Involvement of p44/42 mitogen-activated protein kinases in regulating angiotensin II- and endothelin-1-induced contraction of rat thoracic aorta. Eur J Pharmacol 2002;445:247-256.
62. Lee HM, Lee CK, Lee SH, Roh HY, Bae YM, Lee KY, Lim J, Park PJ, Park TK, Lee YL, Won KJ, Kim B: p38 mitogen-activated protein kinase contributes to angiotensin II-stimulated migration of rat aortic smooth muscle cells. J Pharmacol Sci 2007;105:74-81.
63. Rocic P, Jo H, Lucchesi PA: A role for PYK2 in ANG II-dependent regulation of the PHAS-1-eIF4E complex by multiple signaling cascades in vascular smooth muscle. Am J Physiol Cell Physiol 2003;285:C1437-1444.
64. Sayeski PP, Bernstein KE: Signal transduction mechanisms of the angiotensin II type AT(1)-receptor: looking beyond the heterotrimeric G protein paradigm. J Renin Angiotensin Aldosterone Syst 2001;2:4-10.
65. Suzuki H, Motley ED, Frank GD, Utsunomiya H, Eguchi S: Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents 2005;3:305-322.
66. Ushio-Fukai M, Zuo L, Ikeda S, Tojo T, Patrushev NA, Alexander RW: cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy. Circ Res 2005;97:829-836.